Does Colchicine Substitute Corticosteroids in Treatment of Idiopathic and Viral Pediatric Pericarditis?

Vukomanović, Vladislav; Prijić, Sergej; Krasić, Staša; Borovic, Ruzica; Ninić, Sanja; Nešić, Dejan; Bjelaković, Bojko; Popović, Slobodan; Stajevic, Mila; Petrović, Gordana

doi:10.3390/medicina55100609

Cited by 6 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using polymerase chain reaction (PCR), pericarditis caused by a virus can be diagnosed. It can be treated with nonsteroidal anti-inflammatory drugs, steroidal medications, and colchicine [ 3 ]. According to the literature review, viral infections are linked to pericarditis, with coronavirus disease 2019 (COVID-19) and smallpox patients having a serious but uncommon incidence of pericarditis.…”

Section: Introductionmentioning

confidence: 99%

Monkeypox-Associated Pericarditis: A Maiden Case

Shaik¹,

Voloshyna²,

Nasr³

et al. 2022

Cureus

View full text Add to dashboard Cite

One of the most prevalent causes of pericarditis has been identified as virus infection. However, very little is known regarding cardiac involvement as a consequence of monkeypox infection. We describe a rare case of pericarditis with mild pericardial effusion in an immunocompetent adult with a one-week history of monkeypox. To the best of our knowledge, not many case reports are available in the existing literature. This might be the among the first few cases of monkeypox associated pericarditis during the current pandemic. The use of nonsteroidal anti-inflammatory medications, and colchicine to manage pericarditis has been the cornerstone of the therapy. Within two weeks, the patient reported improvement in his symptoms and the resolution of the pericardial effusion.

show abstract

Section: Introductionmentioning

confidence: 99%

Monkeypox-Associated Pericarditis: A Maiden Case

Shaik¹,

Voloshyna²,

Nasr³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…On the other hand, in addition to its marked anti-inflammatory and anti-fibrotic properties [ 12 ], colchicine has shown, at least in vitro, its effectiveness as an inhibitor of viral replication [ 13 – 15 ]. Treatment with colchicine has shown clinical efficacy in a small series of patients with severe myocarditis [ 16 ] and pericarditis of viral etiology [ 17 ]. In addition, viroporins are viral proteins that alter the permeability of the membrane and can trigger the activation of the inflammatory cascade [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

The effectiveness of early colchicine administration in patients over 60 years old with high risk of developing severe pulmonary complications associated with coronavirus pneumonia SARS-CoV-2 (COVID-19): study protocol for an investigator-driven randomized controlled clinical trial in primary health care—COLCHICOVID study

Estebanez

Alconero

Fernández

et al. 2021

Trials

View full text Add to dashboard Cite

Background There is no strong evidence that any drug is beneficial either for the treatment of SARS-CoV-2 disease or for post-exposure prophylaxis. Therefore, clinical research is crucial to generate results and evaluate strategies against COVID-19. Primary care (PC) centers, the first level of care in the health system, are in a favorable position to carry out clinical trials (CD), as they work with a large volume of patients with varied profiles (from acute to chronic pathologies). During the COVID-19 pandemic, the need for hospital admission and mortality is higher in people > 60 years. Therefore, this is a target population to try to reduce the serious complications and lethality of COVID pneumonia and to avoid overloading the hospital system. Given the pharmacological properties of colchicine (anti-inflammatory and anti-fibrotic, possible inhibition of viral replication, and inhibitory effect on coagulation activation), early treatment with colchicine may reduce the rate of death and serious pulmonary complications from COVID-19 in vulnerable patients. Methods The COLCHICOVID study is a randomized, multicenter, controlled, open-label parallel group (2:1 ratio), phase III clinical trial to investigate the efficacy of early administration of colchicine in reducing the development of severe pulmonary complications associated with COVID-19 infection in patients over 60 years of age with at-risk comorbidities. Discussion This is a pragmatic clinical trial, adapted to usual clinical practice. The demonstration that early administration of colchicine has clinical effectiveness in reducing the complications of SARS-CoV-2 infection in a population highly susceptible may mitigate the health crisis and prevent the collapse of the health system in the successive waves of the coronavirus pandemic. In addition, colchicine is a well-known medicine, simple to use in the primary care setting and with a low cost for the health system. Trial registration ClinicalTrials.govNCT04416334. Registered on 4 June 2020. Protocol version: v 3.0, dated 22 September 2020.

show abstract

Efficacy and Safety of Colchicine in Pediatric Pericarditis: A Systematic Review and Future Directions

Alsabri,

Elsayed,

Elsnhory

et al. 2024

Pediatr Cardiol

View full text Add to dashboard Cite

Does Colchicine Substitute Corticosteroids in Treatment of Idiopathic and Viral Pediatric Pericarditis?

Cited by 6 publications

References 32 publications

Monkeypox-Associated Pericarditis: A Maiden Case

Monkeypox-Associated Pericarditis: A Maiden Case

Efficacy and Safety of Colchicine in Pediatric Pericarditis: A Systematic Review and Future Directions

Contact Info

Product

Resources

About